Cargando…
A landmark in drug discovery based on complex natural product synthesis
Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions....
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572832/ https://www.ncbi.nlm.nih.gov/pubmed/31209263 http://dx.doi.org/10.1038/s41598-019-45001-9 |
_version_ | 1783427727540355072 |
---|---|
author | Kawano, Satoshi Ito, Ken Yahata, Kenzo Kira, Kazunobu Abe, Takanori Akagi, Tsuyoshi Asano, Makoto Iso, Kentaro Sato, Yuki Matsuura, Fumiyoshi Ohashi, Isao Matsumoto, Yasunobu Isomura, Minetaka Sasaki, Takeo Fukuyama, Takashi Miyashita, Yusuke Kaburagi, Yosuke Yokoi, Akira Asano, Osamu Owa, Takashi Kishi, Yoshito |
author_facet | Kawano, Satoshi Ito, Ken Yahata, Kenzo Kira, Kazunobu Abe, Takanori Akagi, Tsuyoshi Asano, Makoto Iso, Kentaro Sato, Yuki Matsuura, Fumiyoshi Ohashi, Isao Matsumoto, Yasunobu Isomura, Minetaka Sasaki, Takeo Fukuyama, Takashi Miyashita, Yusuke Kaburagi, Yosuke Yokoi, Akira Asano, Osamu Owa, Takashi Kishi, Yoshito |
author_sort | Kawano, Satoshi |
collection | PubMed |
description | Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce α-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products. |
format | Online Article Text |
id | pubmed-6572832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65728322019-06-24 A landmark in drug discovery based on complex natural product synthesis Kawano, Satoshi Ito, Ken Yahata, Kenzo Kira, Kazunobu Abe, Takanori Akagi, Tsuyoshi Asano, Makoto Iso, Kentaro Sato, Yuki Matsuura, Fumiyoshi Ohashi, Isao Matsumoto, Yasunobu Isomura, Minetaka Sasaki, Takeo Fukuyama, Takashi Miyashita, Yusuke Kaburagi, Yosuke Yokoi, Akira Asano, Osamu Owa, Takashi Kishi, Yoshito Sci Rep Article Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce α-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products. Nature Publishing Group UK 2019-06-17 /pmc/articles/PMC6572832/ /pubmed/31209263 http://dx.doi.org/10.1038/s41598-019-45001-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kawano, Satoshi Ito, Ken Yahata, Kenzo Kira, Kazunobu Abe, Takanori Akagi, Tsuyoshi Asano, Makoto Iso, Kentaro Sato, Yuki Matsuura, Fumiyoshi Ohashi, Isao Matsumoto, Yasunobu Isomura, Minetaka Sasaki, Takeo Fukuyama, Takashi Miyashita, Yusuke Kaburagi, Yosuke Yokoi, Akira Asano, Osamu Owa, Takashi Kishi, Yoshito A landmark in drug discovery based on complex natural product synthesis |
title | A landmark in drug discovery based on complex natural product synthesis |
title_full | A landmark in drug discovery based on complex natural product synthesis |
title_fullStr | A landmark in drug discovery based on complex natural product synthesis |
title_full_unstemmed | A landmark in drug discovery based on complex natural product synthesis |
title_short | A landmark in drug discovery based on complex natural product synthesis |
title_sort | landmark in drug discovery based on complex natural product synthesis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572832/ https://www.ncbi.nlm.nih.gov/pubmed/31209263 http://dx.doi.org/10.1038/s41598-019-45001-9 |
work_keys_str_mv | AT kawanosatoshi alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT itoken alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT yahatakenzo alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kirakazunobu alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT abetakanori alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT akagitsuyoshi alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT asanomakoto alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT isokentaro alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT satoyuki alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT matsuurafumiyoshi alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT ohashiisao alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT matsumotoyasunobu alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT isomuraminetaka alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT sasakitakeo alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT fukuyamatakashi alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT miyashitayusuke alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kaburagiyosuke alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT yokoiakira alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT asanoosamu alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT owatakashi alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kishiyoshito alandmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kawanosatoshi landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT itoken landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT yahatakenzo landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kirakazunobu landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT abetakanori landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT akagitsuyoshi landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT asanomakoto landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT isokentaro landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT satoyuki landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT matsuurafumiyoshi landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT ohashiisao landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT matsumotoyasunobu landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT isomuraminetaka landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT sasakitakeo landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT fukuyamatakashi landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT miyashitayusuke landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kaburagiyosuke landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT yokoiakira landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT asanoosamu landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT owatakashi landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis AT kishiyoshito landmarkindrugdiscoverybasedoncomplexnaturalproductsynthesis |